Dronabinol Halves Nightmares in PTSD Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Stefan Röpke at Charité–Universitätsmedizin Berlin led a 10-week trial of 171 PTSD patients with frequent, intense nightmares, randomly assigning 87 to dronabinol (purified THC oil, FDA-approved for cancer-related nausea and AIDS-related appetite loss) and 84 to a placebo, with doses escalating from 2.5 mg to a 15 mg maximum taken one hour before bed.
- Dronabinol cut nightmare severity by about 3.7 points on a standard 0-to-8 scale — 1.5 points more than placebo — and 58% of the dronabinol group achieved at least a 50% reduction in nightmare frequency and intensity, compared with 29% on placebo.
- Röpke said the magnitude of effect was the most striking finding: 37% of patients on dronabinol experienced complete cessation of nightmares, more than double the 15% rate in the placebo group.
- THC's psychoactive effects unblinded most participants — about 4 in 5 on dronabinol correctly guessed they were not on placebo, while half of the placebo group believed they had received the active drug, raising questions about expectancy effects.
- Researchers theorize THC may suppress REM sleep, the stage when most vivid dreaming occurs, but Carrie Cuttler at Washington State University flagged that discontinuation triggers REM rebound nightmares, which could drive nightly use and cannabis dependence rather than addressing the root of PTSD.
- Seven participants on dronabinol experienced serious adverse events during the trial, though the researchers attributed none to the treatment; a small uptick in sleep disturbances appeared in the two-week follow-up after the study ended.
Why it matters: Roughly 4% of people globally develop PTSD at some point, and current nightmare-specific treatments are scarce — this trial offers one of the first pharmaceutical options with measurable efficacy, but the REM rebound and unblinding effects mean dronabinol is a symptom suppressant, not a cure, and nightly use carries real dependency risk that physicians must monitor.
Ask SkimNews
